Please assess the completion status of the following clinical trial:

Trial Title: VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed diagnosis of 1 of the following:~  * Acute myelogenous leukemia (AML), meeting the following criteria:~    * In first relapse after first treatment-induced complete remission (CR) (closed to accrual as of 06/09/05)~      * Duration of first CR less than 12 months~     * No prior treatment for first relapse except hydroxyurea~   * FAB type M0, M1, M2, M4-7~   * No acute promyelocytic leukemia~   * No prior treatment with a standard induction regimen containing cytotoxic agents\* (for patients 60 years of age or older)~ * High-risk myelodysplasia, meeting the following criteria:~    * 60 years of age and over~   * No prior cytotoxic chemotherapy\* except hydroxyurea~   * Prior gemtuzumab ozogamicin allowed~   * High risk defined as International Prognostic Scoring System score ≥ 1.5, defined by cytogenetics, % marrow blasts, and lineage cytopenias NOTE: \*Prior low-dose, single-agent cytarabine, decitabine, or azacitidine not considered prior cytotoxic chemotherapy~PATIENT CHARACTERISTICS:~Age~* 18 and over~Performance status~* ECOG 0-2~Life expectancy~* Not specified~Hematopoietic~* Not specified~Hepatic~* Bilirubin ≤ 2.0 mg/dL~* ALT or AST ≤ 5 times upper limit of normal~* Chronic hepatitis allowed~Renal~* Creatinine ≤ 2.0 mg/dL~Cardiovascular~* No myocardial infarction within the past 3 months~* No symptomatic coronary artery disease~* No uncontrolled arrhythmias~* No uncontrolled congestive heart failure~* No other active heart disease~Other~* No uncontrolled active infection~* Not pregnant or nursing~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~Biologic therapy~* Up to 4 leukapheresis procedures allowed during the first 15 days of study treatment~Chemotherapy~* See Disease Characteristics~* Concurrent additional hydroxyurea (maximum dose of 5 g daily for up to 4 days) allowed between days 4 and 15 of each study course to control elevated blast levels~Endocrine therapy~* Not specified~Radiotherapy~* Not specified~Surgery~* Not specified~Other~* Recovered from all prior therapy~* At least 72 hours since prior anti-leukemic treatment with a non-cytotoxic agent~* No concurrent disulfiram (Antabuse)~* No other concurrent anticancer drugs except anagrelide within the first 15 days of study treatment to control elevated platelet counts~* No other concurrent treatment for leukemia, except hydroxyurea used during study treatment~* No other concurrent investigational drugs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).